Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase II multicenter, open-label study of DB107 in adult patients with newly diagnosed HGG

Next Previous
Search
Trial Profile

A phase II multicenter, open-label study of DB107 in adult patients with newly diagnosed HGG

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 27 Jul 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 Jul 2023 New trial record
  • 25 Jul 2023 According to a Denovo Biopharma media release, Noriyuki Kasahara, MD, PhD, is principal Investigator at Brain Tumor Research Center (BTRC) at University of California, San Francisco (UCSF).
  • 25 Jul 2023 According to a Denovo Biopharma media release, the U.S FDA has authorized this phase II trial of DB107 in patients with newly diagnosed high-grade glioma (HGG). Anova Enterprises, Inc. (Anova) will manage the study using its transformative AnovaOS™ technology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top